百利天恒前三季度净利亏损4.95亿元

Core Insights - The company reported a significant decline in revenue and net profit for the first three quarters of 2025, with revenue at 2.066 billion yuan, down 63.52% year-on-year, and a net profit loss of 495 million yuan, down 112.16% year-on-year [1] - In contrast, the third quarter showed a remarkable recovery, with revenue reaching 1.895 billion yuan, an increase of 1625.08% year-on-year, and a net profit of 623 million yuan, marking a turnaround from losses [1] - The increase in third-quarter revenue was attributed to the successful progress of a collaboration with BMS, which triggered a payment of 250 million USD due to the achievement of a milestone in a key clinical trial [1] Financial Performance - For the first three quarters of 2025, the company achieved revenue of 2.066 billion yuan, reflecting a year-on-year decrease of 63.52% [1] - The net profit for the same period was -495 million yuan, indicating a year-on-year decline of 112.16% [1] - In the third quarter alone, the company reported revenue of 1.895 billion yuan, which is a substantial year-on-year increase of 1625.08% [1] - The net profit for the third quarter was 623 million yuan, showing a significant recovery from previous losses [1] Strategic Developments - The company highlighted the successful advancement of its collaboration with BMS, which played a crucial role in the financial performance of the third quarter [1] - A key milestone in the global II/III phase clinical trial, IZABRIGHT-Breast01, was achieved on September 30, leading to the recognition of a payment under the collaboration agreement [1] - The payment of 250 million USD is expected to contribute positively to the company's revenue in the reporting period [1]